Atranorin
Based on 1 Customer Validation
Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 479-20-9
- Formula: C19H18O8
- Molecular Weight:374.34
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | IC50 |
>5 μM
Compound: 4
|
Antiproliferative activity against human HaCaT cells
Antiproliferative activity against human HaCaT cells
|
[PMID: 10395495] |
| PMNL | IC50 |
6 μM
Compound: 4
|
Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells
Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells
|
[PMID: 10395494] |
Atranorin (0.01-10 μg/mL; 3 h) protects SH-SY5Y cells from H2O2-induced cytotoxicity[1].
Atranorin (24 h) inhibits the expression of PD-L1 and TIM-3 in THP-1, KG-1 and Mono-Mac-1 cells, with the mechanism related to AKT pathway inhibition[2].
Atranorin (0-10 μg/mL; 24-72 h) suppresses the migration and invasion of A549 cells. The mechanism involves the inhibition of AP-1, Wnt, STAT pathways and RhoGTPase activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Atranorin (1-5%; topical application as an ointment; once daily; 3-21 days) promotes wound healing in a rat excisional wound model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice aged 8 weeks old treated LLC cells[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; once every 3 days; 2 weeks
-
Result:Significantly reduced tumor volume, tumor weight, and nuclear Ki-67 immunoreactivity.
Downregulated target genes (e.g., KITENIN, STAT, c-myc) in tumor tissues.
-
Animal Model:Male Wistar rats (220-260 g) with full-thickness excisional wounds created by an 8 mm biopsy punch on the back[4]
-
Dosage:1% and 5% in ointment form
-
Administration:Topical application as an ointment; once daily; 3, 7, 14 and 21 days
-
Result:Reduced wound areas significantly on days 3, 7, and 14 (particularly with 5% atranorin).
Induced earlier granulation tissue formation with increased fibroblastic and vascular components.
Improved collagen deposition and organization (with more type I collagen and dense interlaced arrangement in the 5% group).
Modulated myofibroblasts differentiation (reduced early myofibroblasts in the 5% group and promoted timely apoptosis by day 21).
Chemical Information
-
CAS No. 479-20-9
-
Appearance Solid
-
Molecular Weight 374.34
-
Formula C19H18O8
-
Color White to off-white
-
SMILES
O=C(OC1=CC(C)=C(C(OC)=O)C(O)=C1C)C2=C(C)C=C(O)C(C=O)=C2O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 12.5 mg/mL (33.39 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Melo MG, et al. Redox properties and cytoprotective actions of atranorin, a lichen secondary metabolite. Toxicol In Vitro. 2011 Mar;25(2):462-8. [Content Brief]
[3]. Zhou R, et al. The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis. Sci Rep. 2017 Aug 15;7(1):8136. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6714 mL | 13.3568 mL | 26.7137 mL | 66.7842 mL |
| 5 mM | 0.5343 mL | 2.6714 mL | 5.3427 mL | 13.3568 mL | |
| 10 mM | 0.2671 mL | 1.3357 mL | 2.6714 mL | 6.6784 mL | |
| 15 mM | 0.1781 mL | 0.8905 mL | 1.7809 mL | 4.4523 mL | |
| 20 mM | 0.1336 mL | 0.6678 mL | 1.3357 mL | 3.3392 mL | |
| 25 mM | 0.1069 mL | 0.5343 mL | 1.0685 mL | 2.6714 mL | |
| 30 mM | 0.0890 mL | 0.4452 mL | 0.8905 mL | 2.2261 mL |